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Non-small cell lung cancer (NSCLC) is one of the most common causes for lung cancer and
cancer-related death. The imbalance between cell proliferation and apoptosis was suggested to play
an important role in cancer pathogenesis and PKCe is one of the widely recognized targets. Here, we
demonstrate that miR-143 is aberrantly downregulated in NSCLC tissue and negatively correlates
with expression of PKCe. We show that miR-143 speciﬁcally targets the 30-UTR of PKCe and regulates
its expression. Treatment with miR-143 inhibitor mimics cell proliferation and apoptosis imbalance
in NSCLC, while inhibition of PKCe can reverse it. Our ﬁndings suggest that targeting PKCe
overexpression in NSCLC should be beneﬁcial for lung cancer therapy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Imbalance of cell proliferation and apoptosis had been
implicated in multiple cancers, including lung cancer, the most
common one in human beings [1]. It is suggested that both genetic
[2] and environmental [3] factors play critical roles in the etiology
of lung cancer. In the lung cancer cases, non-small cell lung cancer
(NSCLC) accounted for over 80%, indicating its dominant status in
the lung cancer [4]. Currently, there are multiple lines of evidences
suggested that numerous signaling pathways are critical for the
regulation of cell proliferation and apoptosis, and some of them
are speciﬁcally crucial for individual tumor [5]. Thus, to search
for the underlying molecules mediating the disruption of cell
proliferation and apoptosis that is crucial for the pathogenesis of
NSCLC might be an effective therapeutic strategy for lung cancer.
As a small non-coding RNA molecule, microRNA (miRNA) is
universal distributed in both plants and animals and regulating
the targeting gene expression at either transcriptional or post-
transcriptional level [6]. After the ﬁrst two miRNAs were found to
target Bcl-2, an anti-apoptotic molecule that preserve the survival
of malignant B cells so that are important for the pathogenesis
and progression of chronic lymphocytic leukemia [7], the potential
roles of miRNAs in the cancer etiology have been widely studied
and some ofmiRNAswere identiﬁed as oncomirs [8]. In lung cancer,
it is reported that the expression proﬁle of a number of miRNAs aredisrupted [9,10]. Among them, miR-143 (also named as miR-143-
3p) is substantially downregulated. miR-143 is a highly conserved
miRNA that located on chromosome 5 position 33 in the human
genome. Previous studies suggested that abnormal expression of
miR-143 was observed in many cancers [11]. In osteosarcoma, the
decreased level of miR-143 suppresses the apoptosis and promotes
tumorigenicity through targeting Bcl-2 [12]. In lung cancer,
miR-143 was reported to be downregulated in lung carcinoma
tissues and this low level expression of miR-143 was signiﬁcantly
correlated with smoking status [13]. Thus, the inhibition of
miR-143 seems to be important in the pathogenesis of lung cancer.
However, the direct evidence for miR-143 in NSCLC, especially on
the aberrant cell proliferation and apoptosis is not clear.
In this study, we ﬁrst veriﬁed the downregulation of miR-143 in
NSCLC tissues and also found a negative correlation of miR-143
with PKCe, a pro-proliferation and anti-apoptosis gene. We also
identiﬁed that miR-143 speciﬁcally targets on the 30-UTR of PKCe
and suppresses its translation in two different NSCLC cell lines.
Meanwhile, miR-143 inhibition promotes the cell proliferation
and lessens the cell apoptosis depends on PKCe activation. Applica-
tion of PKCe inhibitor of siRNA effectively suppressed cell prolifer-
ation and promoted apoptosis.
2. Materials and methods
2.1. Cell lines
NSCLC cell lines A549 and Calu-1 were obtained from ATCC. The
two cell lines were grown in RPMI 1640 media (Invitrogen, CA,
USA) containing 10% fetal bovine serum at 37 C with 5% CO2.
Table 1
Clinicopathological parameters and miR-143 expression in NSCLC.
Variable Number
of cases
Median expression
of miR-143 (range)
P value
Tumor versus normal
Normal tissue 38 1 ± 0.31 0.021
Lung tumor 38 0.41 ± 0.12
Age
<64 21 0.45 ± 0.34 0.713
>64 17 0.37 ± 0.25
Smoking status
Never smoker 16 0.38 ± 0.32 0.188
Smoker 22 0.44 ± 0.15
Histology
Adenocarcinoma 17 0.37 ± 0.21 0.536
Squamous-cell 21 0.44 ± 0.29
Histological grade
Well/moderately 19 0.38 ± 0.18 0.151
Poorly 19 0.45 ± 0.11
Clinical stage
I/II 23 0.42 ± 0.17 0.663
III 15 0.39 ± 0.14
Tumor diameter
T 6 5 cm 20 0.38 ± 0.19 0.515
T > 5 cm 18 0.41 ± 0.33
Lymph node
Negative 18 0.44 ± 0.16 0.296
Positive 20 0.4 ± 0.29
The data are shown as median (range).
Fig. 1. miR-143 was negatively correlated with PKC in the cancerous tissue of NSCLC pa
corresponding normal tissues. (B) Representative gels for PKC protein levels in NSCLC tis
and matched normal tissues. (D) Correlation between miR-143 expression and PKC prote
experiments. ⁄P < 0.05, compared with the control group.
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Totally 38 primary NSCLC samples without radiotherapy or che-
motherapy prior to surgery and the corresponding non-tumor nor-
mal control samples were obtained from our department between
2010 and 2012. NSCLC disease histology was determined according
to the criteria of WHO and the clinicopathological parameters of
those samples are listed in Table 1. All tissue samples were stored
in liquid nitrogen before RNA extraction and Western blot.
2.3. Plasmids
miR-143 mimic and inhibitor and the corresponding controls
were obtained from RiboBio (Guangzhou, China). PKCe shRNAs
and the scramble control shRNA were designed and generated by
Genechem (Shanghai, China). For luciferase assay, PKCe 30-UTR
containing the potential binding sequences were ampliﬁed with
the following primers: sense, 50-CCCTCGAGTATCTTCGGTAACTTG-
ACA-30 and antisense, 50-TTGCGGCCGCTGAATATGATGGGCAGTA-30.
The fragments were cloned into psiCHECK-2 vector within XhoI
and NotI restriction sites from Progema (WI, USA). Mutation in
the miR-143 binding-sites of PKCe was introduced by whole-
plasmid ampliﬁcation in the seed region of miR-143 (NEB, Ipswich,
Canada).
2.4. RNA extraction and quantitative real-time PCR
Total RNA was extracted with Trizol (Invitrogen), reversely
transcribed using the reverse transcription kit (Toyobo, Tokyo,
Japan). MiRNAs were extracted using the All-in-One miRNAs
reverse transcription kit (Genecopoeia, MD, USA). cDNAs weretients. (A) Relative expression of miR-143 in NSCLC tissues (n = 38) in contrast with
sues and matched normal tissues. (C) Relative mRNA levels of PKC in NSCLC tissues
in levels in NSCLC tissues (Pearson correlation). Data were from three independent
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mix Ex Taq (Takara, Tokyo, Japan) on Stepone plus (Invitrogen).
miR-143 expression was normalized to U6, and PKCe expression
was normalized to GAPDH using 2DDCT method. Primers for
miR-143 and U6 were purchased from GeneCopoeia (CA, USA).
Primers were use for PKCe and GAPDH as following: PKCe sense,
50-AGCCTCGTTCACGGTTCT-30 and antisense, 50-TGTCCAGCCAT-
CATCTCG-30; GAPDH sense, 50-ACGGATTTGGTCGTATTGGGC-30
and antisense, 50-TTGACGGTGCCATGGAATTTG-30.
2.5. Cell proliferation assay
Forty eight hour after transfection, cells were seeded into 96-
well plates at 2000 cells/per well and cultured for 96 h. Cell prolif-
eration was measured using the CCK-8 assay kit (Dojindo, Tokyo,
Japan) according to the manufacturer0s protocol. Absorbance at
450 nm (A450) was detected.
2.6. Apoptosis assay
The Annexin V/FITC and PI apoptosis detection kit was
purchased from Becton Dickinson (NJ, USA). Brieﬂy, 24 h after
transfection, A549 cells were harvested and suspended in Annex-
in-binding buffer, and then cells were incubated with AnnexinFig. 2. miR-143 speciﬁcally targeted PKC in the NSCLC cell lines. (A) Predicted potential t
Luciferase activity assays in A549 cells showed that miR-143 inhibited the expression of
PKC protein levels in Calu-1 cells. Relative mRNA levels of PKC in A549 cells (E) and Ca
experiments. ⁄P < 0.05, compared with the control group.V-FITC and PI for 30 min in the dark at 25 C, Flowjo was used to
analyze the apoptotic percentage of A549 cells.
2.7. Luciferase reporter assays
A549 cells were co-transfected with 0.5 lg of wild type 30-UTR
(WT) or the mutated 30-UTR (Mut) of PKCe and 1 lg of miR-143
or the control mimics. Forty eight hour after transfection, cells
were collected and dual luciferase activity assay was measured
using the dual-luciferase reporter assay kit from Promega (WI,
USA).
2.8. Western blot
Samples were collected and lysed in RIPA buffer (Beytime,
Shanghai, China). Equal amount of proteins from each group were
loaded and separated by 10% SDS–PAGE, tank-based transferred to
polyvinylidene ﬂuoride membrane, and blocked for 0.5 h by block-
ing buffer (Beytime). Membranes were incubated with speciﬁc pri-
mary antibodies (PKCe rabbit monoclonal antibody: ab124806;
GAPDH rabbit polyclonal antibody: ab9485) overnight at 4 C and
followed by horseradish-peroxidase-linked secondary antibodies.
Blots were visualized by ECL (Pierce, IL, USA). Speciﬁc primary
and horseradish-peroxidase-linked secondary antibodies werearget sequences and the mutated sequences of miR-143 in 30-UTR of PKC mRNA. (B)
PKC. (C) miR-143 decreased PKC protein levels in A549 cells. (D) miR-143 decreased
lu-1 cells (F) transfected with miR-143 mimic. Data were from three independent
3664 N. Zhang et al. / FEBS Letters 587 (2013) 3661–3667obtained from Protein Tech (Wuhan, China). Blots were analyzed
by Kodak Digital Science 1D software (Eastman Kodak, CT, USA).
2.9. Statistical analysis
Data were presented as mean ± standard deviation, which were
representative of at least three independent experiments and ana-
lyzed using SPSS 12.0 software (SPSS, IL, USA). Difference was com-
pared by using ANOVA. P < 0.05 was considered as statistical
signiﬁcance.
3. Results
3.1. miR-143 was negatively correlated with PKCe in the cancerous
tissue of NSCLC patients
We ﬁrst performed real time PCR to analyze the alteration of
miR-143 in NSCLC tumor tissues. We found that the level of
miR-143 decreased to 60% of normal tissues (Fig. 1A), which is
consistent with previous report [13]. We then proposed that
miR-143 downregulation might contribute to the pathogenesis
of NSCLC by speciﬁc targeting on some important molecules thatFig. 3. inhibition of miR-143 increased PKC expression in the NSCLC cell lines. Inhibiti
Relative mRNA levels of PKC in A549 cells (C) and Calu-1 cells (D) transfected with anti-m
(F) Relative expression of miR-143 in anti-miR-143 transfected A549 cells. Data were frregulating cell proliferation and apoptosis. By using Targetscan
6.2 (http://www.targetscan.org/) and microRNA.org (http://www.
microrna.org/), and miRSearch 2.0 (http://www.exiqon.com/miR-
Search), we found that the possible target of miR-143 possibly
to be PKCe, a key enzyme in diverse cellular signaling pathways
[14]. We then examined the protein level of PKCe in NSCLC
tissues and found it increased to 1.7folds of normal ones
(Fig. 1B). Concomitantly, no signiﬁcant change was found in the
mRNA level of PKCe between tumor and normal tissues
(Fig. 1C). Furthermore, we found there is a tightly negative corre-
lation of miR-143 level with PKCe protein levels (Fig. 1D), which
indicates the possible translation inhibition of PKCe by miR-143.
According to previously reports, hexokiniase 2 is also the target
of miR-143. We assayed the protein level of hexokinase 2 in the
tumor and normal tissues and did not ﬁnd any differences (data
not shown).
3.2. miR-143 speciﬁcally targeted PKCe in the NSCLC cell lines
To test whether miR-143 could regulate the translation of PKCe
in NSCLC, we ﬁrst performed sequence analysis. We found that
there is a conserved binding site of miR-143 in the 30-UTR regionon of miR-143 increased PKC protein levels in A549 cells (A) and Calu-1 cells (B).
iR-143. (E) Relative expression of miR-143 in miR-143 mimic transfected A549 cells.
om three independent experiments. ⁄P < 0.05, compared with the control group.
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PKCe 30-UTR fragment into the luciferase reporter system and
transfected into A549 cell lines. We found that only the wild-type
but not mutant PKCe reporter displayed obvious inhibition when
co-transfected with miR-143 (Fig. 2B). This result suggested that
miR-143 directly targeted PKCe.
To further demonstrate directly targeting of PKCe by miR-143,
we overexpressed miR-143 in both A549 and Calu-1 cell lines
and assayed the protein and mRNA levels of PKCe. We found that
overexpression of miR-143 caused the decrement of PKCe protein
level (Fig. 2C and D) but not the mRNA level (Fig. 2E and F) in
two cell lines.
We then purchased a speciﬁc antagonimer to inhibit miR-143
(anti-miR-143) expression. We found that in both cell lines,
100 nM anti-miR-143 effectively upregulated the protein level of
PKCe (Fig. 3A and B) without alters mRNA level (Fig. 3C and D).
The effects of both miR-143 mimic and anti-miR-143 on miR-143
levels were detected by qRT-PCR (Fig. 3E and F). These data dem-
onstrated the miR-143 targets on PKCe directly in NSCLC.
3.3. miR-143 inhibition facilitates cell proliferation of NSCLC cells by
activating PKCe
We then query whether miR-143/PKCe signal is involved in the
aberrant cell proliferation and apoptosis in NSCLC. We ﬁrst per-
formed the cell proliferation assay by CCK-8 kit. We found inhibi-
tion of miR-143 mimics the uncontrolled cell proliferation in both
cell lines (Fig. 4A), spontaneously administrated with two speciﬁc
shRNAs to PKCe (Fig. 4C) strongly retards the cell proliferation
(Fig. 4B and D). Furthermore, miR-143 signiﬁcantly increases the
cell apoptosis in A549 cells (Fig. 5A–C). These results suggestedFig. 4. miR-143 inhibition facilitates cell proliferation of NSCLC cells by activating PKC. Ec
cells at 96 h (A). CCK8 assays showed that PKC shRNAs reversed anti-miR-143 mediated
decreased PKC protein levels in A549 cells 72 h after PKC shRNAs transfection (C). Data
control group; #P < 0.05, compared with anti-miR-143 group.that downregulation of miR-143 inhibition increased the cell pro-
liferation that was normally suppressed by PKCe inhibition in
NSCLC cells.
4. Discussion
Here, we explore the detail mechanisms that miR-143 inhibi-
tion in the pathogenesis of NSCLC in two different cell lines,
A549 and Calu-1. We found the downregulation of miR-143 is neg-
atively correlated with PKCe protein in NSCLC tissues. miR-143
speciﬁc targeted on the 30 UTR of PKCe mRNA and suppressed its
translation. Inhibition of miR-143 promotes the cell proliferation
but retards the cell apoptosis, while applying of PKCe inhibitor or
siRNA reverses those abnormalities. These data above elucidate
the possible role of miR-143/PKCe signal in the pathogenesis of
NSCLC.
Like other anti-oncomirs, miR-143 is involved in many cancers
[15]. In an early study, miR-143 was reported to be reduced in a
colorectal neoplasia [16] and several genes encoding signal trans-
duction pathway and chromatin mediated gene expression are
suggested to be the putative targets of miR-143. The level of
miR-143 is also decreased in prostate cancer, which in turn induces
the activation of extracellular signal-regulated kinase-5 [17] and
promotes the cancer cell growth. Meanwhile, miR-143 overexpres-
sion suppressed the prostate cancer cells proliferation and migra-
tion and increased their sensitivity to docetaxel by targeting
EGFR/RAS/MAPK pathway [18]. Thus, to reserve miR-143 might
be a possible therapeutic approach for cancer. The downregulation
of miR-143 in lung cancer was also been reported [13,19] and be
veriﬁed by a systematic meta-analysis [20]. The decreasing of
miR-143 was thought to be the activation of nuclease andtopic overexpression of anti-miR-145 increased the proliferation of A549 and Calu-1
promotion of A549 (B) and Calu-1 (D) cell proliferation. PKC shRNAs signiﬁcantly
were from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01, compared with the
Fig. 5. miR-143 induced apoptosis in A549 cells. A549 cells were transfected with scrambled control (A) or miR-143 mimic (B) for 48 h. Apoptotic percentage was analyzed by
ﬂow cytometry, and shown in (C). Data were from three independent experiments. ⁄⁄P < 0.01, compared with the control group.
3666 N. Zhang et al. / FEBS Letters 587 (2013) 3661–3667chemically modiﬁed miR-143 duplex leads to greater activity and
increased resistance to nuclease, which may be used as a candidate
for an RNA medicine [21].
In our study, we ﬁrstly identiﬁed that PKCewas a target of miR-
143. It is known that among the complicated PKC families, PKCe is
one of the best understood [22]. Overexpression of PKCe increased
the cell ability to grow even without of phorbol 12-myristate 13-
acetate (PMA) [23]. Injection of the 3T3 cell lines with PKCe over-
expression to mice caused the tumours development in vivo. These
lines of evidences demonstrated PKCe as a transforming oncogene.
It was reported that PKCe modulate a lot of pro-tumorigenic sig-
naling pathways. For example, PKCe is known to activate Ras sig-
naling cascade [24–26], one of the best characterized signaling
pathways in cancer biology [27]. As Ras activation caused the
increasing cell cycling by upregulation of cyclin D1 [28,29], PKCe
activation or overexpression will linked with the activation of cy-
clin D1 promoter and increased growth rates [30,31]. Furthermore,
PKCe has also been suggested to regulate the anti-apoptotic signal-
ing pathways by modulating Bcl-2 family members and caspases
[32–34]. Overexpression of PKCe increased the Bcl-2 at both mRNA
and protein levels with a concomitant suppression of Bid, a pro-
apoptotic protein [35]. PKCe also increased the phosphorylation
of Bcl-2 and help the cells to refract from apoptosis [36]. Addition-
ally, PKCe could activate Akt/PKB to exert the pro-survival effects
[37,38]. Thus, to target the PKC overexpression could be an ex-
pected therapeutic method for cancer. Several studies have clearly
demonstrated that miR-143 regulates the expression of hexokinase
2 (HK2) in lung cancer as well as other types of epithelial cancer
[39–41]. Nontheless, our data show that the levels of HK2 are
not changed in NSCLC patients though it could be suppressed by
miR-143 in vitro (data not shown). Further studies are necessary
to verify this issue.
Overall, our study here revealed the negative correlation of
miR-143 and PKCe in NSCLC and targeting PKCe by miR-143 might
be a new treatment approach for NSCLC.
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